OBJECTIVES: Treatment failure is multifactorial. Despite the importance of host cell drug transporters and metabolizing enzymes in the accumulation, distribution and metabolism of drugs targeting intracellular pathogens, their impact on the efficacy of antileishmanials is unknown. We examined the contribution of pharmacologically relevant determinants in human macrophages in the antimony-mediated killing of intracellular Leishmania panamensis and its relationship with the outcome of treatment with meglumine antimoniate. METHODS: Patients with cutaneous leishmaniasis who failed (n = 8) or responded (n =8) to treatment were recruited. Gene expression profiling of pharmacological determinants in primary macrophages was evaluated by quantitative RT-PCR and correlated to the drug-mediated intracellular parasite killing. Functional validation was conducted through short hairpin RNA gene knockdown. RESULTS: Survival of L. panamensis after exposure to antimonials was significantly higher in macrophages from patients who failed treatment. Sixteen macrophage drug-response genes were modulated by infection and exposure to meglumine antimoniate. Correlation analyses of gene expression and intracellular parasite survival revealed the involvement of host cell metallothionein-2A and ABCB6 in the survival of Leishmania during exposure to antimonials. ABCB6 was functionally validated as a transporter of antimonial compounds localized in both the cell and phagolysosomal membranes of macrophages, revealing a novel mechanism of host cell-mediated regulation of intracellular drug exposure and parasite survival within phagocytes. CONCLUSIONS: These results provide insight into host cell mechanisms regulating the intracellular exposure of Leishmania to antimonials and variations among individuals that impact parasite survival. Understanding of host cell determinants of intracellular pharmacokinetics/pharmacodynamics opens new avenues to improved drug efficacy for intracellular pathogens.
OBJECTIVES: Treatment failure is multifactorial. Despite the importance of host cell drug transporters and metabolizing enzymes in the accumulation, distribution and metabolism of drugs targeting intracellular pathogens, their impact on the efficacy of antileishmanials is unknown. We examined the contribution of pharmacologically relevant determinants in human macrophages in the antimony-mediated killing of intracellular Leishmania panamensis and its relationship with the outcome of treatment with meglumine antimoniate. METHODS:Patients with cutaneous leishmaniasis who failed (n = 8) or responded (n =8) to treatment were recruited. Gene expression profiling of pharmacological determinants in primary macrophages was evaluated by quantitative RT-PCR and correlated to the drug-mediated intracellular parasite killing. Functional validation was conducted through short hairpin RNA gene knockdown. RESULTS: Survival of L. panamensis after exposure to antimonials was significantly higher in macrophages from patients who failed treatment. Sixteen macrophage drug-response genes were modulated by infection and exposure to meglumine antimoniate. Correlation analyses of gene expression and intracellular parasite survival revealed the involvement of host cell metallothionein-2A and ABCB6 in the survival of Leishmania during exposure to antimonials. ABCB6 was functionally validated as a transporter of antimonial compounds localized in both the cell and phagolysosomal membranes of macrophages, revealing a novel mechanism of host cell-mediated regulation of intracellular drug exposure and parasite survival within phagocytes. CONCLUSIONS: These results provide insight into host cell mechanisms regulating the intracellular exposure of Leishmania to antimonials and variations among individuals that impact parasite survival. Understanding of host cell determinants of intracellular pharmacokinetics/pharmacodynamics opens new avenues to improved drug efficacy for intracellular pathogens.
Authors: Jill K Paterson; Suneet Shukla; Chelsea M Black; Tokushi Tachiwada; Susan Garfield; Stephen Wincovitch; David N Ernst; Anissa Agadir; Xuelin Li; Suresh V Ambudkar; Gergely Szakacs; Shin-Ichi Akiyama; Michael M Gottesman Journal: Biochemistry Date: 2007-07-28 Impact factor: 3.162
Authors: Partha C Krishnamurthy; Guoqing Du; Yu Fukuda; Daxi Sun; Janardhan Sampath; Kelly E Mercer; Junfeng Wang; Beatriz Sosa-Pineda; K Gopal Murti; John D Schuetz Journal: Nature Date: 2006-09-27 Impact factor: 49.962
Authors: Youssef Abdul Jalil; Vera Ritz; Ana Jakimenko; Christoph Schmitz-Salue; Heike Siebert; David Awuah; André Kotthaus; Thomas Kietzmann; Christina Ziemann; Karen I Hirsch-Ernst Journal: Am J Physiol Cell Physiol Date: 2007-12-26 Impact factor: 4.249
Authors: Zhong Yu; Paul-André Genest; Bas ter Riet; Kate Sweeney; Courtney DiPaolo; Rudo Kieft; Evangelos Christodoulou; Anastassis Perrakis; Jana M Simmons; Robert P Hausinger; Henri G A M van Luenen; Daniel J Rigden; Robert Sabatini; Piet Borst Journal: Nucleic Acids Res Date: 2007-03-27 Impact factor: 16.971
Authors: Luuk C T Dohmen; Adriana Navas; Deninson Alejandro Vargas; David J Gregory; Anke Kip; Thomas P C Dorlo; Maria Adelaida Gomez Journal: J Biol Chem Date: 2016-02-22 Impact factor: 5.157
Authors: Allison K Ehrlich; Olga L Fernández; Daniel Rodriguez-Pinto; Tiago M Castilho; Maria J Corral Caridad; Karen Goldsmith-Pestana; Nancy Gore Saravia; Diane McMahon-Pratt Journal: Infect Immun Date: 2017-02-23 Impact factor: 3.441
Authors: David Rojo; Gisele A B Canuto; Emerson A Castilho-Martins; Marina F M Tavares; Coral Barbas; Ángeles López-Gonzálvez; Luis Rivas Journal: PLoS One Date: 2015-07-10 Impact factor: 3.240